VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Revenue of VistaGen Therapeutics, Inc. (VTGN)
Revenue in 2024 (TTM): $1.06 M
According to VistaGen Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $1.06 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of VistaGen Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $1.06 M | $496 K | $-33,021,000 | $-29,358,000 | $-29,358,000 |
| 2023 | $-227,300 | $-737,100 | $-58,680,800 | $-59,241,800 | $-59,247,700 |
| 2022 | $1.11 M | $293.7 K | $-46,815,900 | $-47,759,000 | $-47,762,400 |
| 2021 | $1.09 M | $1.09 M | $-17,801,000 | $-17,931,600 | $-17,934,200 |
| 2020 | $ | $-103,100 | $-20,653,300 | $-20,771,400 | $-20,774,000 |
| 2019 | $ | $-91,200 | $-24,439,300 | $-24,587,000 | $-24,589,600 |
| 2018 | $ | $-80,700 | $-14,199,600 | $-14,343,500 | $-14,345,900 |
| 2017 | $1.25 M | $1.25 M | $-10,193,200 | $-10,253,100 | $-10,255,500 |
| 2016 | $ | $-53,500 | $-17,798,800 | $-47,218,200 | $-47,220,500 |
| 2015 | $ | $ | $-6,847,700 | $-13,883,400 | $-13,885,800 |
| 2014 | $ | $ | $-4,964,300 | $-2,965,000 | $-2,967,700 |
| 2013 | $200.4 K | $-3,230,400 | $-6,694,600 | $-12,883,000 | $-12,886,700 |
| 2012 | $1.34 M | $1.34 M | $-8,997,800 | $-12,207,900 | $-12,209,500 |
| 2011 | $ | $ | $-8,518 | $-8,946 | $-8,976 |
| 2010 | $ | $ | $-21,540 | $-21,968 | $-21,998 |
| 2009 | $ | $ | $-16,350 | $-16,386 | $-16,416 |
| 2008 | $ | $ | $-4,784 | $-4,784 | $-4,754 |